RESEARCH REPORT
Reinventing biopharma from lab to line
Fueling smarter, faster and scalable biopharma production with intelligent technologies.
5-MINUTE READ
February 10, 2026
In brief
- Biologics now represents 55% of the clinical pipeline, and the increasing complexity of molecules puts pharmaceutical manufacturing under pressure.
- Discovery and clinical trials accelerated by AI and potential supply chain disruptions further complicate manufacturing operations.
- By implementing intelligent technologies, biopharma companies can bring lifesaving therapies to patients faster in the era of Pharma 4.0.
Intelligent technologies accelerate progress in drug manufacturing
Early adopters of digital manufacturing technologies, such as digital process twins, are already harvesting competitive advantages, including bringing lifesaving therapies to patients faster. We ran one of the most comprehensive research efforts to date on digital transformation in biopharmaceutical manufacturing and technical operations and found that companies increasing the adoption of artificial intelligence in drug discovery achieve significant benefits:
- Faster time-to-market: Digital leaders can reduce it by up to 40%.
- Lower production costs: Innovations, such as machine learning and advanced analytics, have dramatically decreased costs. For example, compared to 30 years ago, monoclonal antibody production is 100 times less expensive, dropping from $10,000 to $100 per gram.
- Secure supply of medicines: Digital initiatives boost stability and prevent disruptions, maintaining product availability and meeting patient needs.
However, only a few companies realize these benefits—most find themselves in the challenging middle ground of digital transformation in the pharmaceutical industry.
The roadblocks on the way to scaling digital initiatives
Despite notable progress, most biopharma companies encounter recurring obstacles when attempting to scale digital initiatives:
- Digital pilots are often limited to low-risk, low-impact areas, restricting broader transformation.
- Core data infrastructure and systems remain unprepared to support large-scale digital programs.
- Digital efforts are frequently siloed within individual functions, resulting in fragmented initiatives.
The outcome? Fragmented solutions with limited return on investment, digital initiatives that fail to scale, and a proliferation of “digital dead ends.” These disconnects widen the gap between ambition and execution. If left unresolved, the industry’s digital momentum risks stalling, potentially leading to costly rework and lost opportunities.
The challenge for pharma leaders is no longer whether manufacturing transformation is needed, but how rapidly they can overcome these barriers to scale successful innovations—before constraints become limiting factors in delivering breakthrough therapies to patients. Generative AI now offers a powerful lever, enabling organizations to generate new ideas and solutions at unprecedented scale and speed, helping bridge the gap between vision and execution.
Source: Accenture Analysis
Reinventing the drug lifecycle with AI
Intelligent technologies won’t magically solve all problems biopharma companies are facing. But AI and machine learning have the potential to revolutionize the drug lifecycle, especially in advanced modalities such as antibody–drug conjugates (ADCs). AI in drug development has already shown promise in accelerating development timelines, moving from concept to clinical trials in mere months rather than years.
The full benefits of accelerated R&D can only be realized if the entire drug development process is optimized. Digital technologies offer solutions across technical operations, enabling companies to expedite drug development timelines, moving from concept to clinical trials in mere months rather than years.
Our project work with clients, industry case studies and technical literature highlight the following benefits of implementing intelligent technologies in the drug lifecycle.
When applied across the drug lifecycle, intelligent technologies accelerate development, enhance efficiency and reliability, and reduce costs. They also support more sustainable manufacturing practices—unlocking unprecedented value for biopharma companies.
40%
reduction in time-to-market
30%
throughput improvement in process development
50%
reduction in batch lead time, minimizing work-in-progress inventory
50%
reduction in analysis time, increasing efficiency in deviation investigations
A roadmap for unlocking the value of digital
To scale innovations, biopharma companies need an interconnected system that puts people, data and technology in the center. Only then can they fully embrace data digitalization and intelligent technologies.
A rock-solid foundation like this allows them to build truly resilient operations. To ride out geopolitical policy swings and supply-chain shocks, keep pace with AI-accelerated development timelines, and manage complex pipelines, pharma companies should focus on three key areas:
The future of pharma manufacturing is AI-driven
Pharma, like every other sector, will be inevitably changed by the power of data and AI. For companies ready to act on our recommendations and lead this transformation, the impact will go far beyond incremental gains in isolated metrics. It will redefine how the organizations operate, driving profitability and ultimately benefiting the patients at the heart of it all.
Contributors
The authors would like to thank the following individuals for their contributions to the report:
- Brendan Hughes Ph.D BPHughesCMCConsulting
- Barry Heavey Former Accenture Life Sciences Industry X and Supply Chain & Operations, Global Lead. Now Head of Data Analytics, Sartorius
- Amanda Rubin, Bilal Butt, Camille Planty, Ciara Mc Nally, Joanna Lisiecka, Kamila Ochedalska-Szymanska and Kristina Tomes